Revolution Medicines, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $28.84M, a 1389.11% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $12.21M, a 1270.26% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $4.14M, a 38.12% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.94M, a 55.37% decline year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $21.13M, a 71.40% increase from fiscal 2024.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $12.33M, a 271.83% increase from fiscal 2023.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $3.32M, a 123.90% increase from fiscal 2022.
- Revolution Medicines, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.48M, a 0.40% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $28.84M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $12.21M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $21.13M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $4.14M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.94M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $891.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $12.33M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $4.34M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $810.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $3.32M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $1.01M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $468.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $499.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.48M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $209.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $190.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $305.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $1.49M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $319.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $257.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $555.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $1.88M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $1.39M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $86.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $27.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $114.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $99.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.00K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $14.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $47.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |